Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01150812 · ClinicalTrials.gov registry record · Phase 1
Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01150812 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 9 participants.
The verdict
NCT01150812, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of AZD8165 and the pharmacokinetics of the metabolite AZ12971554 and plasma levels of the prodrug AZD8165 after escalating single oral low doses.
Interventions
- DRUG AZD8165
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01150812
The ClinicalTrials.gov registry entry for NCT01150812 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD8165 is the first listed.
NCT01150812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01150812 about?
NCT01150812 is a clinical study titled "Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects". The purpose of this study is to evaluate the safety and tolerability of AZD8165 and the pharmacokinetics of the metabolite AZ12971554 and plasma levels of the prodrug AZD8165 after escalating single oral low doses.
What is the current status of trial NCT01150812?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2010-06. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01150812?
The interventions under investigation include: AZD8165 (DRUG).
Who is sponsoring clinical trial NCT01150812?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.